Brian Guan-Chyun Liu, serving as a director at CG Oncology, Inc. (NASDAQ: CGON), has executed a significant acquisition of the company's equity. On June 25, 2026, Liu purchased an additional 371,085 shares of CG Oncology common stock. The transaction was valued at approximately $24,814,453, based on a per-share price of $66.87.
This acquisition substantially increases Liu's indirect holdings in the company. Following the transaction, Liu's total indirect ownership stands at 1,886,236 shares. The shares were acquired through Seven Fleet Partners, LP. Liu serves as the managing member of Seven Fleet Advisors, LLC, which acts as the investment manager for Seven Fleet Partners, LP. While this structure grants Liu beneficial ownership of the securities, he has disclaimed beneficial ownership except to the extent of his proportionate pecuniary interest in the shares.
The insider transaction was formally disclosed to the Securities and Exchange Commission on June 29, 2026. At the time of the purchase, the stock was trading at $66.87. Subsequent market activity has pushed the share price higher to $73.73, placing it in close proximity to its 52-week high of $75.50. This price appreciation aligns with a robust 177% return over the past year. Despite this performance, InvestingPro analysis suggests that CGON may be trading above its fair value estimate.
The timing of this insider purchase coincides with significant developments in the company's clinical pipeline and analyst coverage. CG Oncology recently reported positive top-line results from its Phase 2 CORE-008 Cohort CX study. This trial evaluated the combination of cretostimogene grenadenorepvec and gemcitabine in patients diagnosed with high-risk non-muscle invasive bladder cancer. The data indicated a 96% high-grade event-free survival rate at three months, with approximately 90% survival at six months. The study included a median follow-up period of 6.6 months.
Following these clinical updates, analyst sentiment has strengthened. UBS reiterated a Buy rating for CG Oncology and maintained a price target of $90. Truist Securities also upgraded its outlook, raising its price target from $77 to $82. This adjustment reflects increasing interest in emerging therapies for intermediate-risk non-muscle invasive bladder cancer. Previously, Truist had increased its target to $77 from $75, citing the company's revised timeline for submitting its Biologics License Application (BLA) to the fourth quarter of 2026.
Wolfe Research recently initiated coverage on CG Oncology with a Peerperform rating. The firm noted potential approval for the company's creto product in treating high-risk bladder cancer, though they cautioned that the initial launch phase may progress at a slower pace. These developments underscore a growing focus on CG Oncology's efforts to advance treatment options for bladder cancer.